chevron_leftBack
As of 24 April 2025, Cellectis S.A. has a market cap of $110.26M USD, ranking #20193 globally and #280 in France. It ranks #2005 in the Healthcare sector, and #607 in the Biotechnology industry.
Key Stats
Market Cap
$110.26MUSD
96.89M EUR
Enterprise Value
$49.62MUSD
43.79M EUR
Revenue (TTM)
$54.1MUSD
47.54M EUR
EBITDA (TTM)
-$52.82MUSD
-46.61M EUR
Net Income (TTM)
-$40.41MUSD
-35.51M EUR
EBITDA Margin
-98%
Profit Margin
-75%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Andre Choulika
open_in_new
Employees
222
Founded
1999
Website
cellectis.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.2% | -5% | 6.3% | -11% | -25% | -46% |
Upcoming Earnings
Earnings Date
Wed, May 7
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ALCLS
Cellectis SA
ISIN: FR0010425595
Shares Out.:
Shares Outstanding:
72.094M1
Shares Float:
51.488M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.34 EUR | |
|
0WA2
Cellectis SA
ISIN: FR0010425595
|
1.34 EUR | |
|
NASDAQ
MIC: XNAS
|
CLLS
Cellectis SA ADR
ISIN: US15117K1034
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.44 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
